Novartis: mRNA drug targets have great potential March 22, 2018 Source: Sina Pharmaceutical In an effort to open up the lucrative pharmaceutical market in the future, companies that focus on developing targeted messenger ribonucleic acid (mRNA) drugs are undoubtedly at the forefront of competition. For some time, mRNA has been considered a therapeutic drug of choice, but this concept is changing now. A study by Swiss pharmaceutical giants Novartis and the University of North Carolina (UNC) showed that mRNA has great potential when it comes to drug-based drug structures. Novartis/UNC's report in Chemical & Engineering News (C&EN) shows that the structure of mRNA is far more functional than previously thought, especially in the field of disease treatment development. This study suggests that there may be thousands of undiscovered structures in the mRNA. C&EN reports that companies such as Novartis, AstraZeneca, and Pfizer are keen to tap into the potential to "block mRNAs that normally produce pathogenic proteins." The use of mRNA-based drugs to treat certain diseases has shown promise, and many companies are seeing this area as a potential treatment for disease. As part of the research, the researchers developed a method to map the RNA structure of the E. coli transcriptome. As described by C&EN, the combination of a chemical reagent with "high-throughput sequencing" can identify whether the region of RNA is stable or uncontrolled. The team looked at the "most abundant RNA in cells" data and found 194 RNA transcripts encoding 400 genes. This news is bringing shock to the scientific community. Karissa Sanbonmatsu, a scientist at the Los Alamos National Laboratory who is good at RNA research, believes that C&EN's report will "rewrite textbooks." She also said: "Several examples of RNA structures are well known, but this study reveals many of the mRNAs. structure." With this research foundation, Novartis and other drug developers will begin to study the regulation of RNA in the body and how it can be used to treat disease. In an interview, Novartis biologist Razvan Nutiu said his team will study how RNA structure affects body function and how it functions with disease. Novartis has been working on the development of a potential approach to targeting RNA as a treatment for cancer. In addition, the company is exploring the potential of mRNA for cardiovascular, musculoskeletal and neurological research. (Sina Pharmaceutical Compilation / David) Image, article reference source: Https://
HbA1c reflects the average blood sugar control for approximately 3 months. The HbA1c Test serves as an important tool in the diabetes management, allowing healthcare providers to monitor long-term glucose control, evaluate treatment effectiveness, and make informed decisions regarding the individual's diabetes care plan.
BioHermes proudly stands as one of the leading manufacturers dedicated to the field of diabetes diagnostics, encompassing both portable handheld testers and sophisticated benchtop analyzers. Our range caters to various testing environments, including both point-of-care (POCT) and non-POCT settings. With utmost precision and efficiency, our analyzers employ cutting-edge boranate affinity chromatography and high-performance liquid chromatography (HPLC) methodologies.
HbA1c Test, HbA1c Assay, HbA1c Analyzer, Handheld HbA1c Wuxi BioHermes Bio & Medical Technology Co., Ltd. , https://www.biohermesglobal.com